With some of the industry’s top drugs moving toward patent cliffs later this decade, Big Pharma dealmakers have remained active despite economic uncertainties. The 2024 buyouts of Catalent, Alpine Immune Sciences and CymaBay Therapeutics—among others—showed that drugmakers were willing to strike deals for the right assets at the right prices. As the industry navigates the Inflation Reduction Act and other factors, biopharma leaders and venture capitalists on this panel will share their expectations for the year ahead.
